Evidence map›Paper›PMID 36521656›Full record

ReviewCellular signalling2023

COVID-19 signalome: Potential therapeutic interventions.

Kenneth Lundstrom, Altijana Hromić-Jahjefendić, Esma Bilajac, Alaa A A Aljabali, Katarina Baralić, Nagwa A Sabri, Eslam M Shehata, Mohamed Raslan, Sara A Raslan, Ana Cláudia B H Ferreira and 12 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cellular signalling, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 11 institutions in 9 countries.

Kenneth LundstromPanTherapeutics, Route de Lavaux 49, CH1095 Lutry, Switzerland.
Altijana Hromić-JahjefendićDepartment of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Hrasnicka Cesta 15, 71000 Sarajevo, Bosnia and Herzegovina.
Esma BilajacDepartment of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Hrasnicka Cesta 15, 71000 Sarajevo, Bosnia and Herzegovina.
Alaa A A AljabaliDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, P.O. Box 566, Irbid 21163, Jordan.
Katarina BaralićDepartment of Toxicology "Akademik Danilo Soldatović", University of Belgrade - Faculty of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, Serbia.
Nagwa A SabriDepartment of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo 11865, Egypt.
Eslam M ShehataDrug Research Center, Clinical Research and Bioanalysis Department, Cairo 11865, Egypt.
Mohamed RaslanDrug Research Center, Clinical Research and Bioanalysis Department, Cairo 11865, Egypt.
Sara A RaslanDrug Research Center, Clinical Research and Bioanalysis Department, Cairo 11865, Egypt.
Ana Cláudia B H FerreiraCampinas State University, Campinas, São Paulo, Brazil; University Center of Lavras (UNILAVRAS), Lavras, Minas Gerais, Brazil.
Lidiane OrlandiCampinas State University, Campinas, São Paulo, Brazil; University Center of Lavras (UNILAVRAS), Lavras, Minas Gerais, Brazil.
Ángel Serrano-ArocaBiomaterials and Bioengineering Laboratory, Centro de Investigación Traslacional San Alberto Magno, Universidad Católica de Valencia San Vicente Mártir, c/Guillem de Castro 94, 46001, Valencia, Spain.
Vladimir N UverskyDepartment of Molecular Medicine and USF Health Byrd Alzheimer's Institute, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.
Sk Sarif HassanDepartment of Mathematics, Pingla Thana Mahavidyalaya, Maligram 721140, India.
Elrashdy M RedwanDepartment of Biological Sciences, Faculty of Sciences, King Abdulaziz University, P.O. Box 80203, Jeddah, Saudi Arabia.
Vasco AzevedoDepartment of Genetics, Ecology and Evolution, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil.
Khalid J AlzahraniDepartment of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
Khalaf F AlsharifDepartment of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
Ibrahim F HalawaniDepartment of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
Fuad M AlzahraniDepartment of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
Murtaza M TambuwalaLincoln Medical School, University of Lincoln, Brayford Pool Campus, Lincoln LN6 7TS, UK.
Debmalya BarhDepartment of Genetics, Ecology and Evolution, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil; Institute of Integrative Omics and Applied Biotechnology (IIOAB), Nonakuri, Purba Medinipur 721172, India. Electronic address: dr.barh@gmail.com.
Taif University · SAInternational University of Sarajevo · BAUniversidade Estadual de Campinas (UNICAMP) · BRAin Shams University · EGKing Abdulaziz University · SAUniversidade Federal de Minas Gerais · BRUniversity of Belgrade – Faculty of PharmacyUniversity of Lincoln · GBUSF Health Byrd Alzheimer's Institute · USValencia Catholic University Saint Vincent Martyr · ESYarmouk University · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has triggered intensive research and development of drugs and vaccines against SARS-CoV-2 during the last two years. The major success was especially observed with development of vaccines based on viral vectors, nucleic acids and whole viral particles, which have received emergent authorization leading to global mass vaccinations. Although the vaccine programs have made a big impact on COVID-19 spread and severity, emerging novel variants have raised serious concerns about vaccine efficacy. Due to the urgent demand, drug development had originally to rely on repurposing of antiviral drugs developed against other infectious diseases. For both drug and vaccine development the focus has been mainly on SARS-CoV-2 surface proteins and host cell receptors involved in viral attachment and entry. In this review, we expand the spectrum of SARS-CoV-2 targets by investigating the COVID-19 signalome. In addition to the SARS-CoV-2 Spike protein, the envelope, membrane, and nucleoprotein targets have been subjected to research. Moreover, viral proteases have presented the possibility to develop different strategies for the inhibition of SARS-CoV-2 replication and spread. Several signaling pathways involving the renin-angiotensin system, angiotensin-converting enzymes, immune pathways, hypoxia, and calcium signaling have provided attractive alternative targets for more efficient drug development.

Indexed as

COVID-19Antiviral AgentsCOVID-19 VaccinesHumansPandemicsReceptors, VirusSARS-CoV-2Spike Glycoprotein, CoronavirusAntiviral AgentsCOVID-19 VaccinesReceptors, VirusSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Antiviral drugsCOVID-19SARS-CoV-2Signaling pathwaysSignalomeVaccines

Identifiers

PMID36521656
PMCPMC9744501
OpenAlexW4313340091

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.